Astec Lifescienc
Astec Lifescienc Q2 Results 2026 (FY27) statement: Revenue & Margins
Q2 FY27 results statement: what the company reported on revenue, margins and fundraising.
Based on Astec Lifescienc's Q2 FY27 results statement. The company has not published an earnings-call transcript for this quarter, so figures here are what the results statement reports, not management guidance.
The short version
Revenue from operations for the quarter ended 30-Sep-26: - Standalone: Rs. EBITDA (Operating Profit before other income): Not explicitly stated, but Operating margin (%) for Q2 FY27 is -27.48%, down from -9.06% in Q2 FY26 (YoY decline of about 18.42 percentage points). - Operating margin: -27.48% for quarter ended 30-Sep-26 vs -9.06% for quarter ended 30-Sep-25 (significant YoY decline). - Profit after Tax (PAT): Rs.
From Astec Lifescienc's Q2 FY27 earnings-call transcript · updated 27 Oct 2026.
Revenue & Sales Performance
- Revenue from operations for the quarter ended 30-Sep-26:
- Standalone: Rs. 7,202.01 lakh
- Consolidated: Rs. 7,202.01 lakh
- Revenue from operations for the quarter ended 30-Sep-25:
- Standalone: Rs. 7,372.06 lakh
- Consolidated: Rs. 7,372.06 lakh
- Year-on-year change:
- Revenue decreased from Rs. 7,372.06 lakh to Rs. 7,202.01 lakh, approx. -2.3% YoY decline.
2 more points from Astec Lifescienc's call on revenue
Create a free account to keep reading this call
Profitability & Margins
- EBITDA (Operating Profit before other income): Not explicitly stated, but Operating margin (%) for Q2 FY27 is -27.48%, down from -9.06% in Q2 FY26 (YoY decline of about 18.42 percentage points).
- Operating margin: -27.48% for quarter ended 30-Sep-26 vs -9.06% for quarter ended 30-Sep-25 (significant YoY decline).
- Profit after Tax (PAT): Rs. (5,624.88) lakh loss for the quarter ended 30-Sep-26 vs Rs. (5,750.73) lakh loss for quarter ended 30-Sep-25, showing slight improvement in loss.
2 more points from Astec Lifescienc's call on margins
Create a free account to keep reading this call
Fundraising & Capital Structure
- The Standalone Statement of Cash Flows (Page 5) shows:
- Proceeds from issue of shares: Rs. 0.06 lakh for the period ended September 30, 2026.
- Repayment of Long-term Borrowings: Rs. 2,000.00 lakh.
- (Repayment)/Proceeds of short term borrowings (net): Rs. (9,616.05) lakh (repayment).
- Finance cost paid: Rs. (1,525.51) lakh.
- Net cash used in financing activities was Rs. (13,146.90) lakh.
- There is no mention of new long-term borrowings or fresh equity fundraising, except a minor proceeds from share issuance.
2 more points from Astec Lifescienc's call on fundraising
Create a free account to keep reading this call
Top-ranked in Fertilizers & Agrochemicals
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Astec Lifescienc — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹72 Cr, net loss ₹37 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Astec Lifescienc's management said in earlier quarters
Others in Fertilizers & Agrochemicals this season
- Sumitomo Chemical India Ltd (Q2 FY27)
907 crore, down 2% YoY (Q2FY26 revenue was Rs. Key investor presentation takeaways from Sumitomo Chemical India Ltd's Q2 FY27 investor presentation — and how it
- Rallis India (Q2 FY27)
861 Cr. Key investor presentation takeaways from Rallis India's Q2 FY27 investor presentation — and how it ranks against sector peers.
Arthneeti Pro · Annual
Astec Lifescienc and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Astec Lifescienc Q2 FY27 results?
Revenue from operations for the quarter ended 30-Sep-26: - Standalone: Rs. EBITDA (Operating Profit before other income): Not explicitly stated, but Operating margin (%) for Q2 FY27 is -27.48%, down from -9.06% in Q2 FY26 (YoY decline of about 18.42 percentage points). - Operating margin: -27.48% for quarter ended 30-Sep-26 vs -9.06% for quarter ended 30-Sep-25 (significant YoY decline). - Profit after Tax (PAT): Rs.
What is Astec Lifescienc share price analysis?
Astec Lifescienc currently shows a neutral. The stock trades at a P/E of N/A with a market cap of ₹1,455 Cr. Investors should review the full earnings analysis for detailed insights.
Is Astec Lifescienc planning capital expenditure?
The provided pages from the presentation and reports do not contain any explicit details about capex, capacity expansion, or new plant/project plans, including amounts, status, or timelines.
Keep Astec Lifescienc on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's results statement. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.